JP2002504140A - 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 - Google Patents
副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤Info
- Publication number
- JP2002504140A JP2002504140A JP50425999A JP50425999A JP2002504140A JP 2002504140 A JP2002504140 A JP 2002504140A JP 50425999 A JP50425999 A JP 50425999A JP 50425999 A JP50425999 A JP 50425999A JP 2002504140 A JP2002504140 A JP 2002504140A
- Authority
- JP
- Japan
- Prior art keywords
- parathyroid hormone
- months
- administration
- bone
- bone resorption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)ほぼ6から24カ月の期間にわたる副甲状腺ホルモンの投与、および(b)副甲 状腺ホルモンの投与終了後のほぼ6から36カ月の期間にわたる骨吸収抑制剤の投 与に関して適合化された製剤である、副甲状腺ホルモンおよび骨吸収抑制剤を含 む複合型薬学的製剤。 2.ほぼ12から24カ月にわたる副甲状腺ホルモンの投与に関して適合化された、 請求項1記載の複合型薬学的製剤。 3.ほぼ18カ月にわたる副甲状腺ホルモンの投与に関して適合化された、請求項2 記載の複合型薬学的製剤。 4.ほぼ12から36カ月にわたる骨吸収抑制剤の投与に関して適合化された、請求 項1から3のいずれか一項に記載の複合型薬学的製剤。 5.ほぼ12から18カ月にわたる骨吸収抑制剤の投与に関して適合化された、請求 項4記載の複合型薬学的製剤。 6.ほぼ12カ月にわたる骨吸収抑制剤の投与に関して適合化された、請求項5記載 の複合型薬学的製剤。 7.副甲状腺ホルモンが以下のものからなる群より選択される、請求項1から6の いずれか一項に記載の製剤: (a)完全長副甲状腺ホルモン、 (b)完全長副甲状腺ホルモンの生物的活性のある変異体、 (c)生物的活性のある副甲状腺ホルモンの断片、および (d)副甲状腺ホルモンの断片の生物的活性のある変異体。 8.骨吸収抑制剤がビスフォスフォネートである、請求項1から7のいずれか一項 に記載の製剤。 9.ビスフォスフォネートがアレンドロネートである、請求項8記載の製剤。 10.骨吸収抑制剤がエストロゲン様効果をもつ物質である、請求項1から7のいず れか一項に記載の製剤。 11.エストロゲン様効果をもつ物質がエストロゲンである、請求項10記載の製剤 。 12.骨吸収抑制剤が選択的エストロゲン受容体調節因子である、請求項1から7の いずれか一項に記載の製剤。 13.選択的エストロゲン受容体調節因子がラロキシフェン、タモキシフェン、ド ロロキシフェン、トレミフェン、イドキシフェンまたはレボルメロキシフェンか らなる群より選択される、請求項12記載の製剤。 14.骨吸収抑制剤がカルシトニン様物質である、請求項1から7のいずれか一項に 記載の製剤。 15.カルシトニン様物質がカルシトニンである、請求項14記載の製剤。 16.骨吸収抑制剤がビタミンD類似体である、請求項1から7のいずれか一項に記 載の製剤。 17.骨吸収抑制剤がカルシウム塩である、請求項1から7のいずれか一項に記載の 製剤。 18.(a)ほぼ6から24カ月の期間にわたる副甲状腺ホルモンの投与、および(b)副 甲状腺ホルモンの投与終了後のほぼ12から36カ月の期間にわたる骨吸収抑制剤の 投与に関して適合化された医薬品である、骨関連疾患の治療または予防のための 医薬品の製造における骨吸収抑制剤と組み合わせての副甲状腺ホルモンの使用。 19.医薬品がほぼ12から24カ月にわたる副甲状腺ホルモンの投与に関して適合化 された、請求項18記載の使用。 20.医薬品がほぼ18カ月にわたる副甲状腺ホルモンの投与に関して適合化された 、請求項19記載の使用。 21.医薬品がほぼ12から36カ月にわたる骨吸収抑制剤の投与に関して適合化され た、請求項18から20のいずれか一項に記載の使用。 22.ほぼ12から18カ月にわたる骨吸収抑制剤の投与に関して適合化された、請求 項21記載の使用。 23.ほぼ12カ月にわたる骨吸収抑制剤の投与に関して適合化された、請求項22記 載の使用。 24.副甲状腺ホルモンが (a)完全長副甲状腺ホルモン、 (b)完全長副甲状腺ホルモンの生物的活性のある変異体、 (c)生物的活性のある副甲状腺ホルモンの断片、および (d)副甲状腺ホルモンの断片の生物的活性のある変異体 から選択される、請求項18から23のいずれか一項に記載の使用。 25.骨吸収抑制剤が請求項8から17のいずれか一項によって定義される、請求項1 8から24のいずれか一項に記載の使用。 26.骨粗鬆症の治療のための医薬品の製造における請求項18から25のいずれか一 項に記載の使用。 27.骨関連疾患の治療または予防の方法であって、該治療を必要とするヒトを含 む哺乳動物に対して、請求項1から17のいずれか一項に記載の薬学的製剤の有効 量を投与することを含む方法。 28.骨関連疾患の治療または予防の方法であって、該治療を必要とするヒトを含 む哺乳動物に対して、(a)ほぼ6から24カ月の期間にわたる副甲状腺ホルモンの有 効量、および(b)副甲状腺ホルモンの投与終了後のほぼ6から36カ月の期間にわた る骨吸収抑制剤の有効量を投与することを含む方法。 29.ほぼ6から24カ月の期間にわたり副甲状腺ホルモンによる治療をすでに受け た患者に対して、副甲状腺ホルモンの投与終了後にほぼ12から36カ月の期間にわ たって骨吸収抑制剤の有効量を投与することを含む、骨関連疾患の治療または予 防の方法。 30.ほぼ12から24カ月にわたる副甲状腺ホルモンの投与に関して適合化された、 請求項27から29のいずれか一項に記載の骨関連疾患の治療または予防の方法。 31.ほぼ18カ月にわたる副甲状腺ホルモンの投与に関して適合化された、請求項 30記載の骨関連疾患の治療または予防の方法。 32.ほぼ12から36カ月にわたる該骨吸収抑制剤の投与に関して適合化された、請 求項27から31のいずれか一項に記載の骨関連疾患の治療または予防の方法。 33.ほぼ12から18カ月にわたる骨吸収抑制剤の投与に関して適合化された、請求 項32記載の骨関連疾患の治療または予防の方法。 34.ほぼ12カ月にわたる骨吸収抑制剤の投与に関して適合化された、請求項33記 載の骨関連疾患の治療または予防の方法。 35.副甲状腺ホルモンが (a)完全長副甲状腺ホルモン、 (b)完全長副甲状腺ホルモンの生物的活性のある変異体、 (c)生物的活性のある副甲状腺ホルモンの断片、および (d)副甲状腺ホルモンの断片の生物的活性のある変異体 から選択される、請求項27から34のいずれか一項に記載の方法。 36.骨吸収抑制剤が請求項8から17のいずれか一項によって定義される、請求項2 7から35のいずれか一項に記載の方法。 37.骨粗鬆症の治療のための、請求項27から36のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9702401A SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Pharmaceutical use |
SE9702401-2 | 1997-06-19 | ||
PCT/SE1998/001095 WO1998057656A1 (en) | 1997-06-19 | 1998-06-08 | A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010000066A Division JP5525825B2 (ja) | 1997-06-19 | 2010-01-04 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2002504140A true JP2002504140A (ja) | 2002-02-05 |
JP2002504140A5 JP2002504140A5 (ja) | 2005-09-08 |
JP4989811B2 JP4989811B2 (ja) | 2012-08-01 |
Family
ID=20407482
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50425999A Expired - Fee Related JP4989811B2 (ja) | 1997-06-19 | 1998-06-08 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
JP2010000066A Expired - Fee Related JP5525825B2 (ja) | 1997-06-19 | 2010-01-04 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
JP2013206919A Pending JP2014015479A (ja) | 1997-06-19 | 2013-10-02 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010000066A Expired - Fee Related JP5525825B2 (ja) | 1997-06-19 | 2010-01-04 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
JP2013206919A Pending JP2014015479A (ja) | 1997-06-19 | 2013-10-02 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
Country Status (15)
Country | Link |
---|---|
US (8) | US6284730B1 (ja) |
EP (2) | EP1473040B1 (ja) |
JP (3) | JP4989811B2 (ja) |
AT (2) | ATE275419T1 (ja) |
AU (1) | AU753477B2 (ja) |
CA (2) | CA2294101C (ja) |
CY (1) | CY1110287T1 (ja) |
DE (2) | DE69826132T2 (ja) |
DK (2) | DK1473040T3 (ja) |
ES (2) | ES2229511T3 (ja) |
HK (2) | HK1029738A1 (ja) |
PT (2) | PT1473040E (ja) |
SE (1) | SE9702401D0 (ja) |
WO (1) | WO1998057656A1 (ja) |
ZA (1) | ZA984947B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015500333A (ja) * | 2011-12-13 | 2015-01-05 | アモーフィカル リミテッド. | カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム |
US11052107B2 (en) | 2015-06-04 | 2021-07-06 | Amorphical Ltd. | Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates |
US11052108B2 (en) | 2016-10-25 | 2021-07-06 | Amorphical Ltd. | Amorphous calcium carbonate for treating a leukemia |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
AU7410901A (en) | 2000-06-20 | 2002-01-02 | Novartis Ag | Method of administering bisphosphonates |
CA2372450A1 (en) * | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
KR101320817B1 (ko) | 2001-06-01 | 2013-10-21 | 노파르티스 아게 | 부갑상선 호르몬 및 칼시토닌의 경구 투여 |
EP1399135B1 (en) * | 2001-06-28 | 2004-12-29 | Microchips, Inc. | Methods for hermetically sealing microchip reservoir devices |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US7497855B2 (en) * | 2002-09-04 | 2009-03-03 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
WO2005046798A1 (en) * | 2003-11-12 | 2005-05-26 | Nps Allelix Corp. | Treatment of bone loss utilizing full length parathyroid hormone |
CA2595457A1 (en) | 2005-01-25 | 2006-08-03 | Microchips, Inc. | Control of drug release by transient modification of local microenvironments |
CA2607901C (en) | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine |
PT1734251E (pt) * | 2005-06-17 | 2007-03-30 | Magneti Marelli Powertrain Spa | Injector de combustível |
CA2628945A1 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
WO2010115932A1 (en) * | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
ES2663322T3 (es) * | 2009-09-09 | 2018-04-12 | Asahi Kasei Pharma Corporation | Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades |
AU2009356227A1 (en) | 2009-12-07 | 2012-06-21 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
DK3265115T3 (da) * | 2015-03-03 | 2022-09-05 | Radius Health Inc | Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06511233A (ja) * | 1991-05-03 | 1994-12-15 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 骨の形成を促進するための骨成長因子および骨吸収阻害剤 |
JPH07502507A (ja) * | 1991-12-17 | 1995-03-16 | プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド | ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法 |
WO1996007417A1 (en) * | 1994-09-09 | 1996-03-14 | The Procter & Gamble Company | Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3768177A (en) * | 1972-08-02 | 1973-10-30 | R Thomas | Educational device |
US3886132A (en) * | 1972-12-21 | 1975-05-27 | Us Health | Human parathyroid hormone |
US4468464A (en) * | 1974-11-04 | 1984-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Biologically functional molecular chimeras |
US4237224A (en) * | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
US4105602A (en) * | 1975-02-10 | 1978-08-08 | Armour Pharmaceutical Company | Synthesis of peptides with parathyroid hormone activity |
US4016314A (en) * | 1975-06-26 | 1977-04-05 | Hallco Inc. | Embroidered fruit bowl wall hanging and kit for making same |
US4264731A (en) * | 1977-05-27 | 1981-04-28 | The Regents Of The University Of California | DNA Joining method |
US4366246A (en) * | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
US4199060A (en) * | 1978-07-20 | 1980-04-22 | Howard Hardware Products, Inc. | Lock installation kit |
US4425437A (en) * | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
US4383066A (en) | 1980-04-15 | 1983-05-10 | Mitsubishi Gas Chemical Company, Inc. | Polyphenylene ether resin composition |
JPS5825439B2 (ja) | 1980-12-30 | 1983-05-27 | 株式会社林原生物化学研究所 | ヒト副甲状腺ホルモンの製造方法 |
US4394443A (en) * | 1980-12-18 | 1983-07-19 | Yale University | Method for cloning genes |
US4624926A (en) * | 1981-01-02 | 1986-11-25 | The Research Foundation Of State University Of New York | Novel cloning vehicles for polypeptide expression in microbial hosts |
NO163060C (no) | 1981-03-13 | 1990-03-28 | Damon Biotech Inc | Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer. |
US4385212A (en) | 1981-10-05 | 1983-05-24 | Bell Telephone Laboratories Incorporated | Expandable communication terminal housing |
US4424278A (en) * | 1981-11-16 | 1984-01-03 | Research Corporation | Cancer detection procedure using an acyl carrier protein |
US4532207A (en) * | 1982-03-19 | 1985-07-30 | G. D. Searle & Co. | Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase |
US4546082A (en) * | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
US4595658A (en) * | 1982-09-13 | 1986-06-17 | The Rockefeller University | Method for facilitating externalization of proteins synthesized in bacteria |
WO1984001173A1 (en) | 1982-09-15 | 1984-03-29 | Immuno Nuclear Corp | Production of mature proteins in transformed yeast |
DE3312928A1 (de) | 1983-04-11 | 1984-11-22 | Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig | Human-parathormon produzierende hybridvektoren und human-parathormongen |
NZ207926A (en) | 1983-04-25 | 1988-04-29 | Genentech Inc | Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast |
US4588684A (en) * | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
US4637980A (en) | 1983-08-09 | 1987-01-20 | Smithkline Beckman Corporation | Externalization of products of bacteria |
CA1213537A (en) | 1984-05-01 | 1986-11-04 | Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee | Polypeptide expression method |
ATE78515T1 (de) | 1984-10-05 | 1992-08-15 | Genentech Inc | Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung. |
JPS61267528A (ja) * | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | 吸収促進剤を含有するカルシトニン経鼻剤 |
IL77227A (en) | 1984-12-06 | 1992-08-18 | Synergen Biolog Inc | Recombinant methods for production of serine protease inhibitors and methods for isolation of same |
US4822609A (en) * | 1984-12-21 | 1989-04-18 | The Procter & Gamble Company | Treatment of osteoporosis |
US4812311A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
IL78342A (en) | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
US4994559A (en) * | 1985-12-17 | 1991-02-19 | Synergen, Inc. | Human basic fibroblast growth factor |
IE67035B1 (en) | 1986-07-08 | 1996-02-21 | Genetics Inst | Production and use of non-glycosylated IL-6 |
US5420242A (en) * | 1986-10-22 | 1995-05-30 | Kaare M. Gautvik | Production of human parathyroid hormone from microorganisms |
US5010010A (en) * | 1986-10-22 | 1991-04-23 | Selmer-Sande, A.S. | Production of human parathyroid hormone from microorganisms |
AU8172787A (en) | 1986-10-30 | 1988-05-25 | Synergen Biologicals, Inc. | Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same |
FI77278C (fi) | 1986-10-31 | 1989-02-10 | Ahlstroem Oy | Foerfarande och anordning foer foerbraenning av sodasvartlut. |
US4833125A (en) * | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
FR2618914B1 (fr) | 1987-07-31 | 1991-12-06 | Alain Souloumiac | Perfectionnements apportes aux interrupteurs optomagnetiques |
US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
EP0386109A1 (en) | 1987-11-12 | 1990-09-12 | Schering Corporation | Acceleration of bone formation with gm-csf |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5223407A (en) | 1988-08-31 | 1993-06-29 | Allelix Inc. | Excretion of heterologous proteins from e. coli |
US5011678A (en) | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
USRE37919E1 (en) * | 1989-05-12 | 2002-12-03 | The General Hospital Corporation | Recombinant DNA method for production of parathyroid hormone |
US5171670A (en) * | 1989-05-12 | 1992-12-15 | The General Hospital Corporation | Recombinant dna method for production of parathyroid hormone |
DE3935738A1 (de) | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
US5744444A (en) * | 1989-10-27 | 1998-04-28 | Haemopep Pharma Gmbh | HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof |
GB9020544D0 (en) | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
JP2557779B2 (ja) * | 1990-11-26 | 1996-11-27 | アール. レッカー,ロバート | 2成分型骨粗鬆症用薬剤 |
US5563122A (en) * | 1991-12-09 | 1996-10-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilized parathyroid hormone composition |
IT1255723B (it) | 1992-10-09 | 1995-11-13 | Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione | |
TW303299B (ja) | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
US5496801A (en) * | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
WO1996007416A1 (en) | 1994-09-09 | 1996-03-14 | The Procter & Gamble Company | Estrogens and parathyroid hormone for treating osteoporosis |
US5747456A (en) * | 1994-12-19 | 1998-05-05 | Beth Israel Deaconess Medical Center | Continuous low-dose administration of parathyroid hormone or its agonist |
US5550134A (en) | 1995-05-10 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone loss |
US5599822A (en) | 1995-06-06 | 1997-02-04 | Eli Lilly And Company | Methods for minimizing bone loss |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
IL120270A0 (en) | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
US5945412A (en) | 1996-12-09 | 1999-08-31 | Merck & Co., Inc. | Methods and compositions for preventing and treating bone loss |
SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
-
1997
- 1997-06-19 SE SE9702401A patent/SE9702401D0/xx unknown
-
1998
- 1998-06-08 CA CA2294101A patent/CA2294101C/en not_active Expired - Fee Related
- 1998-06-08 AT AT98929965T patent/ATE275419T1/de active
- 1998-06-08 DK DK04017622.4T patent/DK1473040T3/da active
- 1998-06-08 DE DE69826132T patent/DE69826132T2/de not_active Expired - Lifetime
- 1998-06-08 EP EP04017622A patent/EP1473040B1/en not_active Expired - Lifetime
- 1998-06-08 ES ES98929965T patent/ES2229511T3/es not_active Expired - Lifetime
- 1998-06-08 DE DE69841279T patent/DE69841279D1/de not_active Expired - Lifetime
- 1998-06-08 AU AU79458/98A patent/AU753477B2/en not_active Ceased
- 1998-06-08 CA CA2698626A patent/CA2698626C/en not_active Expired - Fee Related
- 1998-06-08 WO PCT/SE1998/001095 patent/WO1998057656A1/en active IP Right Grant
- 1998-06-08 US US09/125,247 patent/US6284730B1/en not_active Expired - Lifetime
- 1998-06-08 AT AT04017622T patent/ATE447410T1/de active
- 1998-06-08 JP JP50425999A patent/JP4989811B2/ja not_active Expired - Fee Related
- 1998-06-08 ES ES04017622T patent/ES2335404T3/es not_active Expired - Lifetime
- 1998-06-08 EP EP98929965A patent/EP1001802B1/en not_active Expired - Lifetime
- 1998-06-08 PT PT04017622T patent/PT1473040E/pt unknown
- 1998-06-08 ZA ZA984947A patent/ZA984947B/xx unknown
- 1998-06-08 PT PT98929965T patent/PT1001802E/pt unknown
- 1998-06-08 DK DK98929965T patent/DK1001802T3/da active
-
2000
- 2000-11-23 HK HK00107524A patent/HK1029738A1/xx not_active IP Right Cessation
-
2001
- 2001-08-31 US US09/942,661 patent/US20020002135A1/en not_active Abandoned
-
2003
- 2003-03-18 US US10/389,797 patent/US7018982B2/en not_active Expired - Fee Related
-
2005
- 2005-04-22 HK HK05103473.5A patent/HK1070816A1/xx not_active IP Right Cessation
- 2005-12-19 US US11/305,339 patent/US7507715B2/en not_active Expired - Fee Related
-
2009
- 2009-01-09 US US12/351,558 patent/US7749543B2/en not_active Expired - Fee Related
-
2010
- 2010-01-04 JP JP2010000066A patent/JP5525825B2/ja not_active Expired - Fee Related
- 2010-01-29 CY CY20101100091T patent/CY1110287T1/el unknown
- 2010-06-23 US US12/822,089 patent/US8153588B2/en not_active Expired - Fee Related
-
2012
- 2012-02-24 US US13/405,093 patent/US8765674B2/en not_active Expired - Fee Related
-
2013
- 2013-10-02 JP JP2013206919A patent/JP2014015479A/ja active Pending
-
2014
- 2014-05-22 US US14/285,437 patent/US20140256632A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06511233A (ja) * | 1991-05-03 | 1994-12-15 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 骨の形成を促進するための骨成長因子および骨吸収阻害剤 |
JPH07502507A (ja) * | 1991-12-17 | 1995-03-16 | プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド | ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法 |
WO1996007417A1 (en) * | 1994-09-09 | 1996-03-14 | The Procter & Gamble Company | Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015500333A (ja) * | 2011-12-13 | 2015-01-05 | アモーフィカル リミテッド. | カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム |
JP2019214631A (ja) * | 2011-12-13 | 2019-12-19 | アモーフィカル リミテッド. | カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム |
US11052107B2 (en) | 2015-06-04 | 2021-07-06 | Amorphical Ltd. | Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates |
US11052108B2 (en) | 2016-10-25 | 2021-07-06 | Amorphical Ltd. | Amorphous calcium carbonate for treating a leukemia |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5525825B2 (ja) | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 | |
CA2151240A1 (en) | Biophosphonate/estrogen therapy for treating and preventing bone loss | |
Fox | Developments in parathyroid hormone and related peptides as bone-formation agents | |
JPH0873376A (ja) | 骨粗鬆症治療薬 | |
JP4931306B2 (ja) | 骨形成を安全に促進させる医薬複合剤 | |
AU2002300896B2 (en) | Method of enhancing bone mineral density | |
Gennari | Calcitonin, bone-active isoflavones and vitamin D metabolites | |
Hodsman | PTH peptides as anabolic agents in bone | |
Patel | Section Review: Oncologic, Endocrine & Metabolic: Drugs in development for the treatment of metabolic bone disease | |
XU et al. | Recent advances in pharmacologic prevention and treatment of osteoporosis | |
Keen et al. | Role and evolution of therapeutic options | |
JPH10203995A (ja) | 抗骨粗鬆症剤 | |
RU98123603A (ru) | Применение компонента гормона роста и лекарственного средства против резорбции костной ткани для периодического (согласованного) лечения остеопороза | |
JPH1192395A (ja) | Pthを含有する歯科治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041210 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041210 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20061006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080509 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080609 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080718 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080711 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080812 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080829 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100316 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100401 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100729 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120501 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |